Organon & Co | OGN - Cash And Equivalent


Organon & Co reported $1.46B in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Celltrion KRW 51.7B 5.1B Jun/2026
Cspc Pharmaceutical CNY 6.09B 1.48B Dec/2025
Deva Holding AS TRY 775.92M 574.67M Sep/2023
Dianthus Therapeutics USD 55.69M 54.86M Sep/2026
Divis Laboratories Ltd INR 1.28B 2.87B Mar/2026
Gilead Sciences USD 3.18B 4.45B Jun/2026
Glaxosmithkline GBP 2.93B 508M Sep/2026
Kangmei Pharma CNY 1.23B 48.16M Mar/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Laboratorios Farma EUR 46.11M 18.92M Jun/2025
Malin Corporation EUR 62.1M 26.4M Dec/2024
Medical Developments International AUD 17.84M 219K Jun/2025
Merck USD 9.55B 2.7B Sep/2026
Neuren Pharmaceuticals AUD 4.23M 1.68M Dec/2025
Novartis USD 8.87B 1.99B Sep/2026
Organigram Holdings CAD 10.85M 6.56M Jun/2026
Organon & Co USD 1.46B 323M Sep/2026
Pharma Mar EUR 19.34M 29.53M Jun/2026
Qiagen NV USD 768.5M 122.21M Jun/2026
Sartorius EUR 230.7M 60.3M Sep/2026
Sino Biopharmaceutical CNY 3.38B 2.09B Dec/2024
Tilray USD 264.83M 43.16M Jun/2025
Zealand Pharma A/S 3.85B 727.54M Mar/2026